연구성과로 돌아가기
JCR 2024 저널 목록 (866 / 2104)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Journal Name | Publisher | ISSN | eISSN | Edition | WoS Category | Total Citation | JIF | JIF Quartile | 상위 JCR(%) | JIF % | JIF Rank | 5-Year JIF | 5-Year Quartile | JIF w/o Self-Cites | Immediacy Index | JCI | JCI Rank | JCI Quartile | JCI Percentile | Eigenfactor Score | Normalized Eigenfactor | Article Influence Score | AIS Quartile | Citable Items | Articles in Citable Items (%) | Cited Half-Life | Citing Half-Life | Total Articles | Citable OA (%) | 수집시기 | 바로가기 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACS Applied Optical Materials | AMER CHEMICAL SOC | 2771-9855 | 2771-9855 | ESCI | MATERIALS SCIENCE, MULTIDISCIPLINARY | 932 | 3.8 | Q2 | 44.0 | 56.0 | 203/460 | 3.8 | Q2 | 3.6 | 0.8 | 0.57 | 226/462 | Q2 | 51.19 | 0.001 | 0.204 | 0.604 | Q2 | 255 | 83.5% | 1.5 | 6.4 | 213 | 17.1% | 2025-08-05 16:03:58 | 바로가기 |
| Advances in Cancer Biology-Metastasis | ELSEVIER | N/A | 2667-3940 | ESCI | ONCOLOGY | 317 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 2.7 | Q3 | 2.8 | 2.6 | 0.57 | 190/326 | Q3 | 41.87 | 0.000 | 0.075 | 0.413 | Q4 | 13 | 100.0% | 2.2 | 6.8 | 13 | 94.1% | 2025-08-05 16:04:25 | 바로가기 |
| Advances in Manufacturing | SPRINGER | 2095-3127 | 2195-3597 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY | 1,890 | 3.8 | Q2 | 44.0 | 56.0 | 203/460 | 4.7 | Q2 | 3.7 | 1.2 | 0.70 | 187/462 | Q2 | 59.63 | 0.001 | 0.290 | 0.758 | Q2 | 66 | 90.9% | 5.0 | 6.1 | 60 | 7.7% | 2025-08-05 16:03:57 | 바로가기 |
| AIDS | LIPPINCOTT WILLIAMS & WILKINS | 0269-9370 | 1473-5571 | SCIE | VIROLOGY | 14,035 | 3.1 | Q2 | 44.0 | 56.0 | 19/42 | 3.3 | Q2 | 2.9 | 1.1 | 0.81 | 18/42 | Q2 | 58.33 | 0.013 | 2.813 | 1.293 | Q1 | 231 | 99.1% | 9.3 | 7.1 | 229 | 22.6% | 2025-08-05 16:05:32 | 바로가기 |
| Anti-Cancer Agents in Medicinal Chemistry | BENTHAM SCIENCE PUBL LTD | 1871-5206 | 1875-5992 | SCIE | ONCOLOGY | 6,048 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 2.8 | Q3 | 2.9 | 0.7 | 0.59 | 185/326 | Q3 | 43.40 | 0.003 | 0.733 | 0.382 | Q4 | 154 | 77.9% | 5.8 | 6.5 | 120 | 2.3% | 2025-08-05 16:04:24 | 바로가기 |
| Brain Behavior & Immunity-Health | ELSEVIER | 2666-3546 | 2666-3546 | ESCI | IMMUNOLOGY | 2,388 | 3.5 | Q2 | 44.0 | 56.0 | 81/183 | 3.9 | Q2 | 3.3 | 0.6 | 0.92 | 53/183 | Q2 | 71.31 | 0.005 | 1.099 | 1.072 | Q2 | 183 | 95.1% | 3.2 | 7.2 | 174 | 93.0% | 2025-08-05 16:03:35 | 바로가기 |
| Brain Tumor Pathology | SPRINGER JAPAN KK | 1433-7398 | 1861-387X | SCIE | ONCOLOGY | 849 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 2.8 | Q3 | 2.9 | 0.9 | 0.65 | 164/326 | Q3 | 49.85 | 0.001 | 0.183 | 0.825 | Q3 | 14 | 92.9% | 7.0 | 6.6 | 13 | 19.7% | 2025-08-05 16:04:25 | 바로가기 |
| BREAST CANCER RESEARCH AND TREATMENT | SPRINGER | 0167-6806 | 1573-7217 | SCIE | ONCOLOGY | 21,736 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 3.6 | Q2 | 2.9 | 0.6 | 0.66 | 160/326 | Q2 | 51.07 | 0.018 | 4.099 | 1.137 | Q2 | 350 | 92.9% | 8.4 | 6.8 | 325 | 39.4% | 2025-08-05 16:04:24 | 바로가기 |
| CLINICAL ONCOLOGY | ELSEVIER SCIENCE LONDON | 0936-6555 | 1433-2981 | SCIE | ONCOLOGY | 4,662 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 3.3 | Q2 | 2.9 | 0.7 | 0.67 | 157/326 | Q2 | 51.99 | 0.005 | 1.154 | 1.098 | Q2 | 128 | 91.4% | 6.8 | 6.1 | 117 | 21.7% | 2025-08-05 16:04:24 | 바로가기 |
| Frontiers in Nanotechnology | FRONTIERS MEDIA SA | N/A | 2673-3013 | ESCI | MATERIALS SCIENCE, MULTIDISCIPLINARY | 1,324 | 3.8 | Q2 | 44.0 | 56.0 | 203/460 | 4.8 | Q2 | 3.8 | 0.7 | 0.35 | 330/462 | Q3 | 28.68 | 0.002 | 0.355 | 0.756 | Q2 | 63 | 63.5% | 3.1 | 5.8 | 40 | 100.0% | 2025-08-05 16:03:57 | 바로가기 |
| Human Vaccines & Immunotherapeutics | TAYLOR & FRANCIS INC | 2164-5515 | 2164-554X | SCIE | IMMUNOLOGY | 14,602 | 3.5 | Q2 | 44.0 | 56.0 | 81/183 | 3.5 | Q2 | 3.2 | 1.0 | 0.77 | 77/183 | Q2 | 58.20 | 0.017 | 3.701 | 0.862 | Q3 | 467 | 84.4% | 4.8 | 4.7 | 394 | 99.2% | 2025-08-05 16:03:34 | 바로가기 |
| IET Nanodielectrics | WILEY | N/A | 2514-3255 | ESCI | MATERIALS SCIENCE, MULTIDISCIPLINARY | 513 | 3.8 | Q2 | 44.0 | 56.0 | 203/460 | 3.4 | Q3 | 3.7 | 1.0 | 0.46 | 277/462 | Q3 | 40.15 | 0.000 | 0.104 | 0.557 | Q3 | 22 | 90.9% | 4.0 | 5.7 | 20 | 96.7% | 2025-08-05 16:03:58 | 바로가기 |
| International Journal of Breast Cancer | WILEY | 2090-3170 | 2090-3189 | ESCI | ONCOLOGY | 561 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 2.9 | Q3 | 3.0 | 0.3 | 0.50 | 216/326 | Q3 | 33.90 | 0.000 | 0.088 | 0.833 | Q3 | 24 | 79.2% | 9.4 | 7.3 | 19 | 100.0% | 2025-08-05 16:04:25 | 바로가기 |
| INTERNATIONAL JOURNAL OF HYPERTHERMIA | TAYLOR & FRANCIS LTD | 0265-6736 | 1464-5157 | SCIE | ONCOLOGY | 6,446 | 3.0 | Q2 | 44.0 | 56.0 | 144/326 | 3.2 | Q2 | 2.6 | 0.5 | 0.81 | 117/326 | Q2 | 64.26 | 0.005 | 1.165 | 0.748 | Q3 | 121 | 90.1% | 6.6 | 6.8 | 109 | 97.6% | 2025-08-05 16:04:24 | 바로가기 |
| International Journal of Mental Health and Addiction | SPRINGER | 1557-1874 | 1557-1882 | SCIE, SSCI | SUBSTANCE ABUSE | 6,382 | 2.5 | Q2 | 44.0 | 56.0 | 26/58 | 4.1 | Q1 | 2.4 | 0.5 | 1.01 | 17/58 | Q2 | 71.55 | 0.009 | 2.059 | 0.968 | Q2 | 193 | 99.0% | 4.3 | 6.8 | 191 | 36.6% | 2025-08-05 16:05:21 | 바로가기 |
페이지 이동: